Recent Updates
Recently added Catalysts
PFE Positive Sentiment

Pfizer Reports Strong Third-Quarter 2026 Results And Raises 2026 Guidance

Key Takeaway: Pfizer Inc. announced robust financial results for Q3 2026, with increased guidance for the full year. The company highlighted strong commercial momentum and disciplined execution. CEO Dr. Albert Bourla noted advancements in their obesity program and recent milestones in oncology, contributing to long-term shareholder value.

Market Sentiment Analysis

POSITIVE FACTORS

  • Pfizer reported strong third-quarter results.
  • Raised full-year 2026 guidance for revenues.
  • Continued advancement in obesity and oncology programs.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+30%
120-day peak, hindsight
Typical move
1.3%
average across 15 past catalysts
Lead asset
ibuzatrelvir
Phase 3 · COVID-19 SARS-CoV-2 Infection

Full Press Release Details

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2026 and raised its full-year 2026 guidance(2) for both Revenues and Adjusted(3) diluted EPS. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: "Pfizer had another strong quarter with commercial momentum and disciplined execution while advancing our strategy for creating long-term shareholder value. Our obesity program continued to advance and recent milestones in oncology, i

Frequently Asked Questions

What were Pfizer's Q3 2026 results?

Pfizer reported strong financial results for Q3 2026.

Did Pfizer raise its 2026 guidance?

Yes, Pfizer raised its full-year 2026 guidance for revenues.

What programs is Pfizer advancing?

Pfizer is advancing its obesity and oncology programs.

Who is the CEO of Pfizer?

Dr. Albert Bourla is the Chairman and CEO of Pfizer.

Last updated: Nov 3, 2026